Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 27 clinical trials at NIH that match your search criteria

Cancer by type: Leukemia

Trial and Protocol Number Leukemia	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia NCI-00-C-0030	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Leukemia (Adult)	Principal Investigator	Referral Contact
Phase II
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia NCI-09-C-0025	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease NCI-09-C-0005	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia NCI-06-C-0177	John E. Janik 301-402-2913	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia NCI-06-C-0150	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Phase II Study of the Efficacy and Toxicity of Ontak® (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia NCI-05-C-0185	John E. Janik 301-402-2913	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia NCI-04-C-0121	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Phase II Trial of BL22 Immunotoxin in Hairy Cell Leukemia NCI-04-C-0014	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
Phase II Study of the Efficacy and Toxicity of CAMPATH-1H in the Therapy of Adult T-Cell Leukemia NCI-03-C-0194	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov
Treatment of Chronic Lymphocytic Leukemia: DNA Microarray Gene Expression Analysis NCI-97-C-0178	Wyndham H. Wilson 301-435-2415	Therese White 301-402-5886 whiteth@mail.nih.gov
Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia NCI-07-C-0130	Robert J. Kreitman 301-496-6947	Linda Ellison 301-496-9458 ellisonl@mail.nih.gov
A Phase I Open-Label Single-Dose Study of Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T-Cell Large Granular Lymphocytic Leukemia NCI-04-C-0089	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

Trial and Protocol Number Leukemia (Childhood)	Principal Investigator	Referral Contact
Phase I
Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors and Leukemias NCI-02-C-0031	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281	Steven Pavletic 301-402-4899	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome NCI-04-C-0055	Daniel Fowler 301-435-8641	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov
Phase I/II
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders NCI-07-C-0195	Michael Bishop 301-435-2764	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov
Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies NCI-01-C-0125	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL) NCI-08-C-0123	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes NCI-07-C-0064	Michael Bishop 301-435-2764	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov
Multi-Institutional Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies NCI-06-C-0227	Anthony J. Murgo 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors for Hematologic Malignancies NCI-04-C-0116	Michael Bishop 301-435-2764	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov
Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas NCI-04-C-0079	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia NCI-06-C-0152	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)

Trial and Protocol Number Solid Tumor (Adult)	Principal Investigator	Referral Contact
Phase I
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas NCI-08-C-0091	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov

Trial and Protocol Number Solid Tumor (Childhood)	Principal Investigator	Referral Contact
Phase I
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study) NCI-07-C-0166	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)